Please select the option that best describes you:
How do you approach G-CSF use when offering neoadjuvant chemoRT for lower extremity soft-tissue sarcoma?
i.e. doxorubicin, ifosfamide + RT. Do you worry about decreased locoregional control or increased toxicities with the use of G-CSF in combination with radiation therapy? If you do administer G-CSF, what is the preferred timing of administration?
Answer from: Medical Oncologist at Academic Institution
We don't use concurrent chemo and XRT so it is not an issue for us. I suppose the detrimental effect of XRT on cycling progenitors would depend on the field that is being irradiated. Typical extremity STS may not pose a big risk, but pelvis would.
Sign in or Register to read more